Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 IV induction and SC maintenance ustekinumab in pediatric Crohn's disease
2019-004225-24Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Efficacy of IV ustekinumab during induction. Started Nov 2020; status: active.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-004225-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004225-24.